Accès ouvert déclaré 2023 article

Predictive multigenic scale. Analysis of own results in metastatic breast cancer

Руслан Маликович Палтуев, Светлана Николаевна Алексахина, Anna S. Artemyeva, E. A. Baychorov, Sergey Yu. Bakharev, Алла Александровна Божок, В. А. Васин, Vladimir Ivanovich Vladimirov, O. A. Volynshchikova, Alexey Yu. Vorontsov, E. A. Gaysina, A. A. Hoffman, Evgeny N. Imyanitov, V. V. Klimenko, Alexander V. Komyakhov, Maia M. Konstantinova, Mikhail V. Kopp, Asel Kudaybergenova, I. A. Lalak, D. L. Matevosyan, Natalia M. Mudzhiri, O. V. Poltareva, O. I. Sevryukova, Владимир Федорович Семиглазов, Т. Yu. Semiglazova, M. M. Urezkova, L. A. Churilova

3Citations signalées, ce qui n’est pas une note de qualité

5Institutions déclarées

1Pays d’affiliation déclarés

Rattachement africain : ru. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Background. Breast cancer is one of the most common female malignancies. Molecular diagnostic methods of tumor profiling allow us to analyze individual tumor characteristics, identify new prognostic and predictive markers. Aim. To increase the efficacy of systemic therapy for breast cancer and reduce inappropriate prescriptions using the data on individual molecular tumor characteristics; to develop a polygenic panel to ensure a tailored approach to systemic therapy for breast cancer. Materials and methods. We analyzed 84 tumor tissue samples from pre- and postmenopausal women with metastatic breast cancer who were treated and followed-up in 6 healthcare institutions. We assessed expression of genes involved in breast cancer. In a pilot study, we analyzed archived paraffin-embedded tumor specimens form 12 out of 1,216 patients with T1–2N0M0 breast cancer included into retrospective analysis. Gene expression was assessed using the nCounter technology based on direct digital detection of targets using fluorescent barcodes (nCounter Analysis System; NanoString Technologies, USA). Tumor tissue (biopsy and surgical specimens) was analyzed. The choice of genes was based on the literature data and experience in the development of other polygenic panels, as well as clinical significance of markers of prognostic scales. Gene mutations were confirmed by next generation sequencing and reverse transcription-polymerase chain reaction. Results. We analyzed the expression of 28 genes with a high predictive value that have been substantially studied (including ESR1, PGR, PIK3CA, BCAR4, BCAS2, CCND1, CCND2, CCND3, FOXA1, Erb2, EGFR, CDH3, FOXC1, KRT14, KRT5, CD274, CDK4, CDK6, P53, PTEN, BRCA1, BRCA2, CHEK2, CLDN3, CLDN7, AR, TOP2a, TUBBIII). We identified 29 cases of discrepancy (29 / 84; 34.5 %) in tumor subtype, including 11 cases of luminal A and B breast cancer, which might potentially affect the choice of the treatment regimen. In 18 cases, there were some principal discrepancies in the tumor subtype that implied totally different treatment regimens. The proposed polygenic signature allows accurate identification of the tumor subtype in patients with metastatic breast cancer and choice of an optimal treatment strategy. Conclusion. We have developed a 100-gene signature including molecular subtypes of breast cancer (luminal A, luminal B, basal, claudin-like) and treatment-oriented clusters. Molecular tumor profiling using this polygenic signature is an accurate method for determining tumor subtype in patients with breast cancer, which enables a tailored approach to therapy.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Predictive multigenic scale. Analysis of own results in metastatic breast cancer
Date Crossref: 25/06/2023
Éditeur: Publishing House ABV Press
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Ministry of Health of the Russian Federation pays non établi dans la notice
Organisme public
State Healthcare Institution "Regional Clinical Oncological Dispensary" pays non établi dans la notice
Organisme public
Nizhny Novgorod Regional Clinical Oncology Center pays non établi dans la notice
Établissement de santé
Samara Medical Institute Reaviz pays non établi dans la notice
Établissement de santé
Research Center of Neurology pays non établi dans la notice
Établissement de santé
N. N. Petrov National Medical Research Center of Oncology pays non établi dans la notice
Structure de recherche
Russian Association of Oncological Mammology pays non établi dans la notice
Organisation à but non lucratif
Stavropol Regional Clinical Oncological Dispensary pays non établi dans la notice
Établissement de santé
Altai Regional Clinical Oncological Dispensary pays non établi dans la notice
Établissement de santé
Russian-Finnish Clinic “Scandinavia” pays non établi dans la notice
Établissement de santé
Ivanovo Regional Oncological Dispensary pays non établi dans la notice
Institution
Pyatigorsk Interdistrict Oncological Dispensary pays non établi dans la notice
Institution

Ministry of Health of the Russian Federation, State Healthcare Institution "Regional Clinical Oncological Dispensary" et Nizhny Novgorod Regional Clinical Oncology Center, avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Advanced Breast Cancer TherapiesCancer Genomics and DiagnosticsBreast Cancer Treatment Studies

Consulter la publication primaire Ouvrir le DOI